Oppenheimer & Co. Inc. Has $1.76 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Oppenheimer & Co. Inc. increased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 36.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,564 shares of the company’s stock after acquiring an additional 5,999 shares during the period. Oppenheimer & Co. Inc.’s holdings in AstraZeneca were worth $1,758,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of AZN. Price T Rowe Associates Inc. MD grew its holdings in shares of AstraZeneca by 17.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after acquiring an additional 9,002,450 shares in the last quarter. Capital World Investors grew its stake in AstraZeneca by 0.3% in the first quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock valued at $634,525,000 after purchasing an additional 29,497 shares in the last quarter. Envestnet Asset Management Inc. increased its position in AstraZeneca by 16.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock worth $266,565,000 after purchasing an additional 488,644 shares during the last quarter. Clearbridge Investments LLC raised its stake in shares of AstraZeneca by 5.8% during the 2nd quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after purchasing an additional 186,010 shares in the last quarter. Finally, Fayez Sarofim & Co lifted its holdings in shares of AstraZeneca by 4.7% during the 1st quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock valued at $202,588,000 after buying an additional 134,784 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

AZN opened at $63.23 on Monday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The firm has a market capitalization of $196.05 billion, a P/E ratio of 30.25, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The stock’s 50 day moving average price is $75.03 and its two-hundred day moving average price is $78.23. The company has a quick ratio of 0.69, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the firm posted $0.87 earnings per share. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. On average, equities analysts forecast that AstraZeneca PLC will post 4.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AZN. TD Cowen increased their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.